Integra LifeSciences Holdings received a high momentum style score — 5 notes

Analysts at Zacks have given a high momentum style score to Integra LifeSciences, an integrated medical technology company offering solutions in orthopedic extremity, neurosurgery and reconstructive and general surgery.

Advertisement

Here are five notes:

 

1. The style score is calculated based on a series of factors indicating whether the stock is at a favorable level to enter a position based on the recent upward or downward movement of the equity.

 

2. Only expert traders use this strategy, which is determined by short-term price movements rather than company fundamentals or research.

 

3. Based on a consensus basis, brokerage firm research analysts predict Integra LifeSciences stock to increase to $65.50.

 

4. Analysts at Zacks placed a stock rating of 2.14 on the equity of Integras LifeSciences stock.

 

5. Analysts predict Integra LifeSciences will report earnings of $0.76 per share on August 8, 2015.

 

For more articles on device news:

Hill-Rom purchases Welch Allyn for $2.05B — 7 key notes

Blue Belt, SurgCenter Development partner for orthopedic robotics: 5 key notes

Michael Turpin joins K2M board of directors — 5 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.